MedTrace Logo

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

NCT02131636 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

Conditions

  • Erythema
  • Rosacea

Interventions

DRUG

AGN-199201

AGN-199201 applied to the face once daily for 29 days.

DRUG

Vehicle to AGN-199201

Vehicle to AGN-199201 applied to the face once daily for 29 days.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-11-30
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02131636 on ClinicalTrials.gov